ReviewClinical medicine (London, England)2025
Management of acute decompensated cirrhosis.
Review in Clinical medicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Challenging times in medical education in the era of artificial intelligence can provide opportunities.Clinical medicine (London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute decompensated cirrhosis (AD) refers to the development of ascites, encephalopathy, gastrointestinal haemorrhage, or any combination of these disorders in a patient with known or previously undiagnosed advanced chronic liver disease. It carries a significant mortality, particularly if associated with organ failure (acute on chronic liver failure (ACLF)). Admissions with AD have increased by 50% over the last decade, and liver-related deaths have increased by 64% in the last 20 years. UK-wide reports and audits, including by the National Confidential Enquiry into Patient Outcome and Death, have revealed unwarranted variation in care and outcomes for patients with AD. This article summarises the management of patients admitted with AD, including the British Society of Gastroenterology (BSG) / British Association for the Study of the Liver (BASL) / Society of Acute Medicine (SAM) decompensated cirrhosis care bundle, developed for completion in the first 6 h of admission to standardise care for these complex patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.